Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth Prices $40M Public Offering

NEW YORK – MDxHealth said Friday that it has priced a registered public offering of 10 million American Depositary Shares (each representing 10 ordinary shares of the company) at $4.00 per share for gross proceeds of $40 million.

The company has also granted underwriters a 30-day option to purchase 1.5 million additional ADSs on the same terms and conditions. Cowen and Company and William Blair & Company are acting as joint bookrunning managers, with BTIG serving as lead manager and KBC Securities as co-manager for the offering.

MDxHealth said the offering is expected to close on Feb. 7, and it plans to use the net proceeds for general corporate and working capital purposes, including product development efforts and commercial activities.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.